Regulation of erythropoietin receptor activity in endothelial cells by different erythropoietin (EPO) derivatives: An in vitro study

International Journal of Molecular Sciences

Volumn 14, Issue 2, 2013, Pages 2258-2281

  Trincavelli, Maria Letizia ^a   Da Pozzo, Eleonora ^a   Ciampi, Osele ^a   Cuboni, Serena ^a   Daniele, Simona ^a   Abbracchio, Maria Pia ^b   Martini, Claudia ^a  

^a UNIVERSITY OF PISA   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Angiogenesis; Cell proliferation; Endothelial cells; Erythropoiesis stimulating agents; Erythropoietin receptor; Receptor desensitization; Signal resensitization; STAT 5 pathway

Indexed keywords

CONTINUOUS ERYTHROPOIESIS RECEPTOR ACTIVATOR; ERYTHROPOIETIN RECEPTOR; NOVEL ERYTHROPOIESIS STIMULATING PROTEIN; RECOMBINANT ERYTHROPOIETIN; STAT5A PROTEIN; VASCULOTROPIN;

ANGIOGENESIS; ARTICLE; CELL PROLIFERATION; CELL STIMULATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EXPOSURE; DRUG MECHANISM; DRUG RESPONSE; HUMAN; HUMAN CELL; IN VITRO STUDY; PHARMACOKINETICS; PROTEIN FUNCTION; RECEPTOR DOWN REGULATION; REGULATORY MECHANISM; SENSITIZATION; TRANSCRIPTION INITIATION; UMBILICAL VEIN ENDOTHELIAL CELL;

EID: 84875103840     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms14022258     Document Type: Article

References (64)

1. Erslev, A. Humoral regulation of red cell production. Blood 1953, 8, 349-357.
2. Lai, P.H.; Everett, R.; Wang, F.F.; Arakawa, T.; Goldwasser, E. Structural characterization of human erythropoietin. J. Biol. Chem. 1986, 261, 3116-3121.
3. Bazan, J.F. Structural design and molecular evolution of a cytokine receptor superfamily. Proc. Natl. Acad. Sci. USA 1990, 87, 6934-6938.
4. Lin, C.S.; Lim, S.K.; D'Agati, V.; Costantini, F. Differential effects of an erythropoietin receptor gene disruption on primitive and definitive erythropoiesis. Genes Dev. 1996, 10, 154-164.
5. Anagnostou, A.; Liu, Z.; Steiner, M.; Chin, K.; Lee, E.S.; Kessimian, N.; Noguchi, C.T. Erythropoietin receptor mRNA expression in human endothelial cells. Proc. Natl. Acad. Sci. USA 1994, 91, 3974-3978.
6. Morishita, E.; Masuda, S.; Nagao, M.; Yasuda, Y.; Sasaki, R. Erythropoietin receptor is expressed in rat hippocampal and cerebral cortical neurons and erythropoietin prevents in vitro glutamate-induced neuronal death. Neuroscience 1997, 76, 105-116.
7. Banerjee, D.; Rodriguez, M.; Nag, M.; Adamson, J.W. Exposure of endothelial cells to recombinant human erythropoietin induces nitric oxide synthase activity. Kidney Int. 2000, 57, 1895-1904.
8. Stasko, J.; Drouet, L.; Soria, C.; Mazoyer, E.; Caen, J.; Kubisz, P. Erythropoietin and granulocyte colony-stimulating factor increase plasminogen activator inhibitor-1 release in HUVEC culture. Thromb. Res. 2002, 105, 161-164.
9. Congote, L.F.; Sadvakassova, G.; Dobocan, M.C.; Difalco, M.R.; Li, Q. Erythropoietin-dependent endothelial proteins: Potential use against erythropoietin resistance. Cytokine 2010, 51, 113-118.
10. Noguchi, C.T.; Wang, L.; Rogers, H.M.; Teng, R.; Jia, Y. Survival and proliferative roles of erythropoietin beyond the erythroid lineage. Expert Rev. Mol. Med. 2008, 10, e36.
11. Heeschen, C.; Aicher, A.; Lehmann, R.; Fichtlscherer, S.; Vasa, M.; Urbich, C.; Mildner-Rihm, C.; Martin, H.; Zeiher, A.M.; Dimmeler, S. Erythropoietin is a potent physiologic stimulus for endothelial progenitor cell mobilization. Blood 2003, 102, 1340-1346.
12. Santhanam, A.V.; d'Uscio, L.V.; Peterson, T.E.; Katusic, Z.S. Activation of endothelial nitric oxide synthase is critical for erythropoietin-induced mobilization of progenitor cells. Peptides 2008, 29, 1451-1455.
13. Westenbrink, B.D.; Lipsic, E.; van der Meer, P.; van der Harst, P.; Oeseburg, H.; Du Marchie Sarvaas, G.J.; Koster, J.; Voors, A.A.; van Veldhuisen, D.J.; van Gilst, W.H.; et al. Erythropoietin improves cardiac function through endothelial progenitor cell and vascular endothelial growth factor mediated neovascularization. Eur. Heart. J. 2007, 28, 2018-2027.
14. Brines, M.; Cerami, A. Discovering erythropoietin's extra-hematopoietic functions: Biology and clinical promise. Kidney Int. 2006, 70, 246-250.
15. Haller, H.; Christel, C.; Dannenberg, L.; Thiele, P.; Lindschau, C.; Luft, F.C. Signal transduction of erythropoietin in endothelial cells. Kidney Int. 1996, 50, 481-488.
16. Yang, J.; Xiao, Z.; Li, T.; Gu, X.; Fan, B. Erythropoietin promotes the growth of pituitary adenomas by enhancing angiogenesis. Int. J. Oncol. 2012, 40, 1230-1237.
17. Kawachi, K.; Iso, Y.; Sato, T.; Wakabayashi, K.; Kobayashi, Y.; Takeyama, Y.; Suzuki, H. Effects of erythropoietin on angiogenesis after myocardial infarction in porcine. Heart Vessels 2012, 27, 79-88.
18. Carlini, R.G.; Reyes, A.A.; Rothstein, M. Recombinant human erythropoietin stimulates angiogenesis in vitro. Kidney Int. 1995, 47, 740-745.
19. Ahn, S.; Min, S.K.; Min, S.I.; Suh, J.H.; Kim, S.J.; Ha, J. Early sustained injections of erythropoietin improve angiogenesis and restoration of perfusion in the ischemic mouse hindlimb. J. Korean Med. Sci. 2012, 27, 1073-1078.
20. Ribatti, D.; Presta, M.; Vacca, A.; Ria, R.; Giuliani, R.; Dell'Era, P.; Nico, B.; Roncali, L.; Dammacco, F. Human erythropoietin induces a pro-angiogenic phenotype in cultured endothelial cells and stimulates neovascularization in vivo. Blood 1999, 93, 2627-2636.
21. Constantinescu, S.N.; Ghaffari, S.; Lodish, H.F. The erythropoietin receptor: Structure, activation and intracellular signal transduction. Trends Endocrinol. Metab. 1999, 10, 18-23.
22. Fliser, D.; Bahlmann, F.H. Erythropoietin and the endothelium-A promising link? Eur. J. Clin. Invest. 2008, 38, 457-461.
23. Marzo, F.; Lavorgna, A.; Coluzzi, G.; Santucci, E.; Tarantino, F.; Rio, T.; Conti, E.; Autore, C.; Agati, L.; Andreotti, F. Erythropoietin in heart and vessels: Focus on transcription and signaling pathways. J. Thromb. Thrombolysis 2008, 26, 183-187.
24. Janmaat, M.L.; Heerkens, J.L.; de Bruin, A.M.; Klous, A.; de Waard, V.; de Vries, C.J. Erythropoietin accelerates smooth muscle cell-rich vascular lesion formation in mice through endothelial cell activation involving enhanced PDGF-BB release. Blood 2010, 115, 1453-1460.
25. Fusté, B.; Serradell, M.; Escolar, G.; Cases, A.; Mazzara, R.; Castillo, R.; Ordinas, A.; Díaz-Ricart, M. Erythropoietin triggers a signaling pathway in endothelial cells and increases the thrombogenicity of their extracellular matrices in vitro. Thromb Haemostasis 2002, 88, 678-685.
26. Su, K.H.; Shyue, S.K.; Kou, Y.R.; Ching, L.C.; Chiang, A.N.; Yu, Y.B.; Chen, C.Y.; Pan, C.C.; Lee, T.S. β Common receptor integrates the erythropoietin signaling in activation of endothelial nitric oxide synthase. J. Cell Physiol. 2011, 226, 3330-3339.
27. Locatelli, F.; Olivares, J.; Walker, R.; Wilkie, M.; Jenkins, B.; Dewey, C.; Gray, S.J. Novel erythropoiesis stimulating protein for treatment of anemia in chronic renal insufficiency. Kidney Int. 2001, 60, 741-747.
28. Elliott, S.; Pham, E.; Macdougall, I.C. Erythropoietins: A common mechanism of action. Exp. Hematol. 2008, 36, 1573-1584.
29. Klingmuller, U.; Lorenz, U.; Cantley, L.C.; Neel, B.C.; Lodish, H.C. Specific recruitment of SH-PTP1 to the erythropoietin receptor causes inactivation of JAK2 and termination of proliferative signals. Cell 1995, 80, 729-738.
30. Mufson, R.A.; Gesner, T.G. Binding and internalization of recombinant human erythropoietin in murine erythroid precursor cells. Blood 1987, 69, 1485-1490.
31. Levin, I.; Cohen, J.; Supino-Rosin, L.; Yoshimura, A., Watowich, S.S.; Neumann, D. Identification of a cytoplasmic motif in the erythropoietin receptor required for receptor internalization. FEBS Lett. 1998, 427, 164-170.
32. Zuo, G.; Guan, T.; Chen, D.; Li, C.; Jiang, R.; Luo, C.; Hu, X.; Wang, Y.; Wang, J. Total saponins of Panax ginseng induces K562 cell differentiation by promoting internalization of the erythropoietin receptor. Am. J. Chin. Med. 2009, 37, 747-757.
33. Sulahian, R.; Cleaver, O.; Huang, L.J. Ligand-induced EpoR internalization is mediated by JAK2 and p85 and is impaired by mutations responsible for primary familial and congenital polycythemia. Blood 2009, 113, 5287-5297.
34. Flint-Ashtamker, G.; Eisen-Lev, R.; Cohen, J.; Huang, L.J.; Neumann, D. Amino acid residues 268-276 of the erythropoietin receptor contain an endocytosis motif and are required for erythropoietin-mediated proliferation. FEBS Lett. 2002, 518, 189-194.
35. Walrafen, P.; Verdier, F.; Kadri, Z.; Chrétien, S.; Lacombe, C.; Mayeux, P. Both proteasomes and lysosomes degrade the activated erythropoietin receptor. Blood 2005, 105, 600-608.
36. Verdier, F.; Walrafen, P.; Hubert, N.; Chretien, S.; Gisselbrecht, S.; Lacombe, C.; Mayeux, P. Proteasomes regulate the duration of erythropoietin receptor activation by controlling downregulation of cell surface receptors. J. Biol. Chem. 2000, 275, 18375-18381.
37. Yen, C.H.; Yang, Y.C.; Ruscetti, S.K.; Kirken, R.A.; Dai, R.M.; Li, C.C. Involvement of the ubiquitin-proteasome pathway in the degradation of nontyrosine kinase-type cytokine receptors of IL-9, IL-2 and erythropoietin. J. Immunol. 2000, 165, 6372-6380.
38. Müller, J.; Sperl, B.; Reindl, W.; Kiessling, A.; Berg, T. Discovery of chromone-based inhibitors of the transcription factor STAT5. ChemBioChem 2008, 9, 723-727.
39. Małyszko, J.S.; Małyszko, J.; Pawlak, K.; Pawlak, K.; Buczko, W.; Myśliwiec, M. Importance of serotonergic mechanisms in the thrombotic complications in hemodialyzed patients treated with erythropoietin. Nephron 2000, 84, 305-311.
40. Borawski, J.; Mysliwiec, M. Effects of recombinant erythropoietin therapy on circulating endothelial markers in hemodialysis patients. Clin. Appl. Thromb. Hemostasis 2002, 8, 77-84.
41. Staško, J.; Kubisz, P. Increased soluble thrombomodulin in hemodialysis patients with long-term erythropoietin treatment: What does it reflect? Clin. Appl. Thromb. Hemostasis 2003, 9, 349-352.
42. Taylor, J.E.; Belch, J.J.F.; McLaren, M.; Henderson, J.S.; Stewart, W.K. Effect of erythropoietin therapy and withdrawal on blood coagulation and fibrinolysis in hemodialysis patients. Kidney Int. 1993, 44, 182-190.
43. Pawlak, K.; Pawlak, D.; Mysliwiec, M. Long-term erythropoietin therapy does not affect endothelial markers, coagulation activation and oxidative stress in haemodialyzed patients. Thromb. Res. 2007, 120, 797-803.
44. Bahlmann, F.H.; Song, R.; Boehm, S.M.; Mengel, M.; von Wasielewski, R.; Lindschau, C.; Kirsch, T.; de Groot, K.; Laudeley, R.; Niemczyk, E.; et al. Low-dose therapy with the long-acting erythropoietin analogue darbepoetin alpha persistently activates endothelial Akt and attenuates progressive organ failure. Circulation 2004, 110, 1006-1012.
45. Kanellakis, P.; Pomilio, G.; Agrotis, A.; Gao, X.; Du, X.J.; Curtis, D.; Bobik, A. Darbepoetin-mediated cardioprotection after myocardial infarction involves multiple mechanisms independent of erythropoietin receptor-common beta-chain heteroreceptor. Br. J. Pharmacol. 2010, 160, 2085-2096.
46. Baker, J.E.; Kozik, D.; Hsu, A.K.; Fu, X.; Tweddell, J.S. Gross G.J. Darbepoetin alfa protects the rat heart against infarction: Dose-response, phase of action and mechanisms. J. Cardiovasc. Pharmacol. 2007, 49, 337-345.
47. Opie, L.H. Erythropoietin as a cardioprotective agent: Down, but not out. Heart 2011, 97, 1537-1539.
48. Minamino, T.; Toba, K.; Higo, S.; Nakatani, D.; Hikoso, S.; Umegaki, M.; Yamamoto, K.; Sawa, Y.; Aizawa, Y.; Komuro, I. Design and rationale of low-dose erythropoietin in patients with ST-segment elevation myocardial infarction (EPO-AMI-II study): A randomized controlled clinical trial. Cardiovasc. Drugs Ther. 2012, 26, 409-416.
49. Inrig, J.K.; Bryskin, S.K.; Patel, U.D.; Arcasoy, M.; Szczech, L.A. Association between high-dose erythropoiesis-stimulating agents, inflammatory biomarkers and soluble erythropoietin receptors. BMC Nephrol. 2011, 12, 67-77.
50. Sawyer, S.T.; Penta, K. Association of JAK2 and STAT5 with erythropoietin receptors. Role of receptor phosphorylation in erythropoietin signal transduction. J. Biol. Chem. 1996, 271, 32430-32437.
51. Ji, Y.Q.; Zhang, Y.Q.; Li, M.Q.; Du, M.R.; Wei, W.W.; Li, D.J. EPO improves the proliferation and inhibits apoptosis of trophoblast and decidual stromal cells through activating STAT-5 and inactivating p38 signal in human early pregnancy. Int. J. Clin. Exp. Pathol. 2011, 4, 765-774.
52. Mezentsev, A.; Merks, R.M.; O'Riordan, E.; Chen, J.; Mendelev, N.; Goligorsky, M.S.; Brodsky, S.V. Endothelial microparticles affect angiogenesis in vitro: Role of oxidative stress. Am. J. Physiol. Heart Circ. Physiol. 2005, 289, H1106-H1114.
53. Aranda, E.; Owen, G.I. A semi-quantitative assay to screen for angiogenic compounds and compounds with angiogenic potential using the EA. hy926 endothelial cell line. Biol. Res. 2009, 42, 377-389.
54. El-Komy, M.H.; Schmidt, R.L.; Widness, J.A.; Veng-Pedersen, P. Differential pharmacokinetic analysis of in vivo erythropoietin receptor interaction with erythropoietin and continuous erythropoietin receptor activator in sheep. Biopharm. Drug Dispos. 2011, 32, 276-288.
55. Bulut, G.B.; Sulahian, R.; Ma, Y.; Chi, N.W.; Huang, L.J. Ubiquitination regulates the internalization, endolysosomal sorting and signaling of the erythropoietin receptor. J. Biol. Chem. 2011, 286, 6449-6457.
56. Suzuki, N.; Ohneda, O.; Takahashi, S.; Higuchi, M.; Mukai, H.Y.; Nakahata, T.; Imagawa, S.; Yamamoto, M. Erythroid-specific expression of the erythropoietin receptor rescued its null mutant mice from lethality. Blood 2002, 100, 2279-2288.
57. Meyer, L.; Deau, B.; Forejtníková, H.; Duménil, D.; Margottin-Goguet, F.; Lacombe, C.; Mayeux, P.; Verdier, F. beta-Trcp mediates ubiquitination and degradation of the erythropoietin receptor and controls cell proliferation. Blood 2007, 109, 5215-5222.
58. Macdougall, I.C. Novel erythropoiesis-stimulating agents: A new era in anemia management. Clin. J. Am. Soc. Nephrol. 2008, 3, 200-207.
59. Elliott, S.; Egrie, J.; Browne, J.; Lorenzini, T.; Busse, L.; Rogers, N.; Ponting, I. Control of rHuEPO biological activity: The role of carbohydrate. Exp. Hematol. 2004, 32, 1146-1155.
60. Gross, A.W.; Lodish, H.F. Cellular trafficking and degradation of erythropoietin and novel erythropoiesis stimulating protein (NESP). J. Biol. Chem. 2006, 281, 2024-2032.
61. Macdougall, I.C. CERA (Continuous erythropoietin receptor activator): A new erythropoiesis-stimulating agent for the treatment of anemia. Curr. Hematol. Rep. 2005, 4, 436-440.
62. Macdougall, I.C.; Robson, R.; Opatrna, S.; Liogier, X.; Pannier, A.; Jordan, P.; Dougherty, F.C.; Reigner, B. Pharmacokinetics and pharmacodynamics of intravenous and subcutaneous continuous erythropoietin receptor activator (CERA) in patients with chronic kidney disease. Clin. J. Am. Soc. Nephrol. 2006, 1, 1211-1215.
63. Jarsch, M.; Brandt, M.; Lanzendörfer, M.; Haselbeck, A. Comparative erythropoietin receptor binding kinetics of CERA and epoetin-beta determined by surface plasmon resonance and competition binding assay. Pharmacology 2008, 81, 63-69.
64. Egrie, J.C.; Browne, J.K. Development and characterization of novel erythropoiesis stimulating protein (NESP). Nephrol. Dial. Transplant. 2001, 16, 3-13.